• Je něco špatně v tomto záznamu ?

Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas

M. Hubáčková, R. Václavíková, M. Ehrlichová, M. Mrhalová, R. Kodet, K. Kubáčková, D. Vrána, I. Gut, P. Souček

. 2012 ; 130 (2) : 338-348.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022314

Grantová podpora
NS9799 MZ0 CEP - Centrální evidence projektů

Associations of transcript levels of oxidative stress-modifying genes SOD2, SOD3, NQO1 and NQO2 and their functional single nucleotide polymorphisms (SNPs) rs4880, rs1799895, rs2536512, rs699473, rs1800566 and rs1143684 with prognosis of breast cancer patients were studied. SNPs were assessed by allelic discrimination in a cohort of 321 breast cancer patients from the Czech Republic. Transcript levels were determined by real-time polymerase chain reaction (PCR) with absolute quantification in tumor and adjacent non-neoplastic control tissues. Both genotypes and transcript levels were then compared with available clinical data on patients. Patients carrying low activity allele Leu in NQO2 rs1143684 had a greater incidence of stage 0 or I disease (i.e., better prognosis) than patients with the Phe/Phe genotype. This association was more evident in patients without expression of progesterone receptors (p = 0.031). Patients carrying the Thr allele in SOD3 rs2536512 SNP had a significantly greater incidence of tumors expressing estrogen receptors than patients carrying the Ala/Ala genotype (p = 0.007). SOD3 transcript level was significantly higher in grade 1 or 2 tumors than in grade 3 tumors (p = 0.006). Patients carrying T allele in SOD3 rs699473 SNP had significantly poorer progression-free survival (PFS) than patients carrying the CC genotype (p = 0.038). The same applied to the subgroup of patients treated by hormonal regimens (p = 0.021). Patients carrying the high activity Ala/Ala genotype in SOD2 (rs4880) had significantly poorer PFS than Val allele carriers in the group treated by cyclophosphamide but not hormonal regimens (p = 0.004). Our results suggest that NQO2, SOD2 and SOD3 may significantly modify prognosis of breast cancer patients and that their significance should be further characterized.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022314
003      
CZ-PrNML
005      
20140904084852.0
007      
ta
008      
120806s2012 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1002/ijc.26006 $2 doi
035    __
$a (PubMed)21351093
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hubáčková, Miluše. $7 _AN026440 $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.
245    10
$a Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas / $c M. Hubáčková, R. Václavíková, M. Ehrlichová, M. Mrhalová, R. Kodet, K. Kubáčková, D. Vrána, I. Gut, P. Souček
520    9_
$a Associations of transcript levels of oxidative stress-modifying genes SOD2, SOD3, NQO1 and NQO2 and their functional single nucleotide polymorphisms (SNPs) rs4880, rs1799895, rs2536512, rs699473, rs1800566 and rs1143684 with prognosis of breast cancer patients were studied. SNPs were assessed by allelic discrimination in a cohort of 321 breast cancer patients from the Czech Republic. Transcript levels were determined by real-time polymerase chain reaction (PCR) with absolute quantification in tumor and adjacent non-neoplastic control tissues. Both genotypes and transcript levels were then compared with available clinical data on patients. Patients carrying low activity allele Leu in NQO2 rs1143684 had a greater incidence of stage 0 or I disease (i.e., better prognosis) than patients with the Phe/Phe genotype. This association was more evident in patients without expression of progesterone receptors (p = 0.031). Patients carrying the Thr allele in SOD3 rs2536512 SNP had a significantly greater incidence of tumors expressing estrogen receptors than patients carrying the Ala/Ala genotype (p = 0.007). SOD3 transcript level was significantly higher in grade 1 or 2 tumors than in grade 3 tumors (p = 0.006). Patients carrying T allele in SOD3 rs699473 SNP had significantly poorer progression-free survival (PFS) than patients carrying the CC genotype (p = 0.038). The same applied to the subgroup of patients treated by hormonal regimens (p = 0.021). Patients carrying the high activity Ala/Ala genotype in SOD2 (rs4880) had significantly poorer PFS than Val allele carriers in the group treated by cyclophosphamide but not hormonal regimens (p = 0.004). Our results suggest that NQO2, SOD2 and SOD3 may significantly modify prognosis of breast cancer patients and that their significance should be further characterized.
650    _2
$a nádory prsu $x krev $x enzymologie $x genetika $x patologie $7 D001943
650    _2
$a kohortové studie $7 D015331
650    _2
$a DNA nádorová $x krev $x genetika $7 D004273
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a NAD(P)H dehydrogenasa (chinon) $x biosyntéza $x genetika $7 D016660
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a chinonreduktasy $x biosyntéza $x genetika $7 D011808
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a superoxiddismutasa $x biosyntéza $x genetika $7 D013482
650    _2
$a genetická transkripce $7 D014158
650    _2
$a nádorové biomarkery $x biosyntéza $x genetika $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Václavíková, Radka $7 xx0142918
700    1_
$a Ehrlichová, Marie $7 xx0067467
700    1_
$a Mrhalová, Marcela $7 xx0062381
700    1_
$a Kodet, Roman, $d 1953- $7 nlk19990073380
700    1_
$a Kubáčková, Kateřina $7 xx0083614
700    1_
$a Vrána, David $7 xx0103187
700    1_
$a Gut, Ivan, $d 1936- $7 xx0060370
700    1_
$a Souček, Pavel $7 xx0060511
773    0_
$w MED00002298 $t International journal of cancer. Journal international du cancer $x 1097-0215 $g Roč. 130, č. 2 (2012), s. 338-348
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21351093 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20140904085246 $b ABA008
999    __
$a ok $b bmc $g 944227 $s 779611
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 130 $c 2 $d 338-348 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
GRA    __
$a NS9799 $p MZ0
LZP    __
$a Pubmed-20120806/12/01

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace